Shares of Curis, Inc. (NASDAQ:CRIS) have been given a consensus rating of “Hold” by the six analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $6.50.

A number of research analysts recently issued reports on CRIS shares. Zacks Investment Research upgraded shares of Curis from a “sell” rating to a “hold” rating in a report on Monday, July 17th. ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, BidaskClub upgraded shares of Curis from a “strong sell” rating to a “sell” rating in a report on Thursday, August 17th.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/01/curis-inc-cris-given-consensus-recommendation-of-hold-by-analysts.html.

Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its position in Curis by 58.7% during the 1st quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 13,448 shares during the period. Prudential Financial Inc. acquired a new stake in Curis during the 1st quarter valued at approximately $105,000. Dynamic Technology Lab Private Ltd increased its position in Curis by 22.3% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 41,922 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 7,638 shares during the period. OxFORD Asset Management LLP acquired a new stake in Curis during the 2nd quarter valued at approximately $115,000. Finally, Voya Investment Management LLC increased its position in Curis by 21.8% during the 2nd quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 12,207 shares during the period. 44.72% of the stock is owned by institutional investors and hedge funds.

Shares of Curis (NASDAQ:CRIS) opened at 1.49 on Friday. The stock’s 50 day moving average is $1.81 and its 200 day moving average is $2.12. Curis has a 12 month low of $1.47 and a 12 month high of $3.72. The firm’s market cap is $214.38 million.

Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The business had revenue of $2.10 million during the quarter, compared to the consensus estimate of $2.08 million. Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The firm’s quarterly revenue was up 23.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.09) EPS. Analysts forecast that Curis will post ($0.40) EPS for the current fiscal year.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Stock Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related stocks with our FREE daily email newsletter.